Stephen Reale, MD
Internal Medicine · van Nuys, CANPI 1396846572
Payments from drug & device makers
Across 191 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$865
- Amgen$413
- Lilly USA, LLC$283
- Novo Nordisk$210
- Philips North America LLC$198
- Boehringer Ingelheim$198
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,071100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 47 | $865 |
| Amgen | 20 | $413 |
| Lilly USA, LLC | 12 | $283 |
| Novo Nordisk | 11 | $210 |
| Philips North America LLC | 11 | $198 |
| Boehringer Ingelheim | 8 | $198 |
| Phathom Pharmaceuticals, Inc. | 7 | $194 |
| AstraZeneca | 8 | $184 |
| Vanda Pharmaceuticals Inc. | 5 | $147 |
| GSK | 5 | $146 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $135 |
| Pfizer | 7 | $131 |
| Sanofi-aventis U.S. LLC | 4 | $95 |
| Merck | 4 | $94 |
| Astellas Pharma US Inc | 4 | $79 |
| Gilead | 2 | $56 |
| Biogen | 2 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $52 |
| Sunovion Pharmaceuticals Inc. | 2 | $43 |
| Dexcom, Inc. | 2 | $39 |
| Biohaven Pharmaceuticals, Inc. | 2 | $36 |
| Exact Sciences | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Topcon Healthcare Solutions, Inc. | 1 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $30 |
| Edwards Lifesciences | 1 | $27 |
| Nevro Corp. | 1 | $26 |
| Strongbridge US Inc. | 1 | $26 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Alkermes, Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $24 |
| Linus Health, Inc. | 1 | $23 |
| Novartis | 1 | $20 |
| Eisai Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Bayer | 1 | $16 |
| Shire North American Group Inc | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Apria Healthcare LLC | 1 | $12 |
How this compares
$4,071 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 76 | $97,084 |
| JanuviaSitagliptin Phosphate | 64 | $67,309 |
| OzempicSemaglutide | 63 | $65,381 |
| FarxigaDapagliflozin Propanediol | 28 | $28,755 |
| TradjentaLinagliptin | 23 | $28,718 |
| JardianceEmpagliflozin | 18 | $28,384 |
| MounjaroTirzepatide | 15 | $26,732 |
| XareltoRivaroxaban | 27 | $24,925 |
| TrulicityDulaglutide | 11 | $24,870 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $23,647 |
| ProliaDenosumab | 11 | $18,632 |
| TrintellixVortioxetine Hydrobromide | 29 | $16,773 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $15,679 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $14,364 |
| LinzessLinaclotide | 14 | $14,221 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $131 | $99,94296 claims |
| MerckJanuvia, Belsomra | $94 | $76,15284 claims |
| Novo NordiskOzempic | $210 | $65,38163 claims |
| Boehringer IngelheimTradjenta, Jardiance | $198 | $57,10241 claims |
| Lilly USA, LLCMounjaro, Trulicity | $283 | $51,60126 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $146 | $39,32644 claims |
| AstraZenecaFarxiga | $184 | $28,75528 claims |
| AbbVieLinzess, Lexapro, Synthroid | $865 | $24,19654 claims |
| AmgenProlia | $413 | $18,63211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in van Nuys
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.